Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)
Retrieved on:
Tuesday, March 2, 2021
The results from the Phase II INTERACT study are being evaluated to determine next steps for development activities.
Key Points:
- The results from the Phase II INTERACT study are being evaluated to determine next steps for development activities.
- "The Phase II INTERACT study was a well-designed and executed clinical study that resulted in a negative outcome for luvadaxistat on the primary endpoint assessing the change from baseline in negative symptoms of schizophrenia.
- "The totality of the top-line data from this study therefore support further clinical evaluation of luvadaxistat.
- These approaches do not impact the negative symptoms of schizophrenia or cognitive impairment associated with schizophrenia (CIAS), suggesting that dysfunction of the dopamine system might not fully explain the negative and cognitive symptoms associated with schizophrenia.